https://shrodotorg.wordpress.com/molecular-mechanisms-of-cancer-signal-transduction-program/

After his studies in Biochemistry at Universita’ degli Studi Milano, Milan Italy, Dr. Morrione moved to USA in 1993 and has been working in the field of cancer biology since his postdoctoral training at the Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA in the laboratory of Dr. Renato Baserga, one of the leading experts in IGF-IR oncogenic signaling. In 1997 Dr. Morrione joined the Faculty of Thomas Jefferson University in the Department of Microbiology. In 2002 after receiving an NIH/NIDDK Career Development Award Dr. Morrione joined the Department of Urology at Jefferson where from 2008 to 2018 serves as the Director for Urology Basic Science and Associate Professor. Dr. Morrione joined the Department of Biology and the Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology as Associate Professor of Research, and he is currently professor of Research and Deputy Director of the Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology.

Dr. Morrione has made several important discoveries in determining the role of growth factor receptors in transformation. He is the author of 85 peer-reviewed publications and book chapters and serves as a member of numerous editorial boards of high impact factor journals, including Matrix Biology, Cancers and Frontiers in Endocrinology (Cancer Endocrinology).

In recent years Dr. Morrione built an NIH funded program in the investigation of growth factor signaling (progranulin) in bladder cancer. Additional research programs focus on the role of tumor suppressors of the RB family in various tumor models.

As expert in cancer cell signaling, he has served on several organizing committees, chaired sessions and presented his work at numerous international meetings. Dr. Morrione has acted as expert reviewer on Study Sections for NIH, the American Urological Association (AUA) and BCAN (Bladder Cancer Advocacy Network) and serves as expert reviewer for numerous funding agencies including The Research Grants Council (RGC) of Hong Kong, AIRC (AssociazioneItaliana Ricerca sul Cancro), Breast Cancer Campaign, UK, Genome British Columbia and Diabetes, UK.